SEC Comment Letter 0000000000-24-001762 to RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd.
Date: Feb. 14, 2024 · CIK: 0001553846 · Accession: 0000000000-24-001762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276979
Letter
United States securities and exchange commission logo February 14, 2024 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv 6473921 Israel Re:RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed February 9, 2024 File No. 333-276979 Dear Dror Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alla Digilova, Esq.
Show Raw Text
United States securities and exchange commission logo
February 14, 2024
Dror Ben-Asher
Chief Executive Officer
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
Re:RedHill Biopharma Ltd.
Registration Statement on Form F-1
Filed February 9, 2024
File No. 333-276979
Dear Dror Ben-Asher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alla Digilova, Esq.